1. Freuer D, Linseisen J, O’Mara TA, et al. Body fat distribution and risk of breast, endometrial, and ovarian cancer: a two-sample mendelian randomization study. Cancers (Basel). 2021;13(20):5053.
2. Quail DF, Dannenberg AJ. The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol. 2019;15(3):139-154.
3. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901-1914.
4. Lajous M, Banack HR, Kaufman JS, Hernán MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. Am J Med. 2015;128(4):334-336.
5. Bradshaw PT, Cespedes Feliciano EM, Prado CM, et al. Adipose tissue distribution and survival among women with nonmetastatic breast cancer. Obesity (Silver Spring). 2019;27(6):997-1004.
6. Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA. Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control. 2015;26(12): 1803-1811.
7. Kim MS, Choi YJ, Lee YH. Visceral fat measured by computed tomography and the risk of breast cancer. Transl Cancer Res. 2019;8(5):1939-1949.
8. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012; 21(8):1244-1259.
9. Crudele L, Piccinin E, Moschetta A. Visceral adiposity and cancer: role in pathogenesis and prognosis. Nutrients. 2021;13(6):2101.
10. WHO Classification of Tumours Editorial Board. Breast tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series,5thed.; vol.2). Available from:https://tumourclassification.iarc.who.int/chapters/32
11. van Gemert WA, Monninkhof EM, May AM, et al. Association between changes in fat distribution and biomarkers for breast cancer. Endocr Relat Cancer. 2017;24(6):297-305.
12. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378-397.
13. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007;8(5):395-408.
14. Smith SG, Sestak I, Morris MA, et al. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. Breast Cancer Res Treat. 2021;188(1):215-223.
15. Ayoub NM, Yaghan RJ, Abdo NM, Matalka II, Akhu-Zaheya LM, Al-Mohtaseb AH. Impact of obesity on clinicopathologic characteristics and disease prognosis in pre- and postmenopausal breast cancer patients: a retrospective institutional study. J Obes. 2019;2019:3820759.
16. Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer. 2018;26(3):861-868.
17. Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287.
18. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013;34(1):1-11.
19. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010;121(2):261-271.
20. Tiwari P, Blank A, Cui C, et al. Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. J Exp Med. 2019;216(6):1345-1358.